Page 11 - Evaluate Safety News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article FORT COLLINS, Colo., Feb. 16, 2021 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company creating first second-generation immune therapies, today provided an update regarding its CYTO-200 portfolio of clinical programs. Cytocom has submitted an Investigational New Drug (IND) application with updated protocols to the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial, to evaluate the safety and efficacy of CYTO-205 to slow or halt the progression of the SARS-CoV-2, the virus that causes COVID-19. Preclinical in vitro s...

INO-4800 COVID-19 Vaccine Description INO-4800 is a DNA vaccine candidate matched to the novel coronavirus SARS-CoV-2, which causes the COVID-19 disease in humans.  INOVIO's INO-4800 is the only nucleic-acid-based vaccine stable at room temperature for more than a year and does not require frozen transport or for years of storage, which are important factors when implementing mass immunizations to battle the current pandemic, says INOVIO. The INO-4800 vaccine contains the plasmid pGX9501, which encodes for the entire length of the Spike glycoprotein of SARS-CoV-2. Inovio's proprietary pla...

Home / Top News / Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021 CHATHAM, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) — T...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research ... Tonix Pharmaceuticals Holding Corp.January 5, 2021 GMT Expands Ongoing Research Collaboration Between Tonix and MGH Studying TNX-1500 in Heart Transplantation TNX-1500 May Hold Potential in Treating Autoimmune Diseases Including Systemic Lupus Erythematosus, Rheumatoid Arthritis and Multiple Sclerosis CHATHAM, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the ...

Search jobs 24-Dec-2020 Innovative drug, Carrimycin, Receives FDA Approval for International, Multi-country Phase III Clinical Trial for the treatment of severe COVID-19 in hospitalized patients Shenyang Tonglian Group Co., Ltd. announces FDA approval for a randomized, multicenter, placebo-controlled, double-blind clinical study of the safety and efficacy of Carrimycin for the treatment of severe COVID-19 in hospitalized patients International 300-patient study, to start in January 2021 and run for ~6 months in the USA, Mexico, Brazil, Philippines,...